{"id":"NCT02447848","sponsor":"Talphera, Inc","briefTitle":"Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain","officialTitle":"A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for the Treatment of Acute Pain in Patients in Emergency Room Setting","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10","primaryCompletion":"2016-06","completion":"2016-07","firstPosted":"2015-05-19","resultsPosted":"2017-10-19","lastUpdate":"2017-10-19"},"enrollment":76,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Moderate-to-severe Acute Pain"],"interventions":[{"type":"DRUG","name":"sufentanil sublingual 30 mcg tablet","otherNames":[]}],"arms":[{"label":"sufentanil sublingual tablet 30 mcg","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety and efficacy of sufentanil tablet (ST) 30 mcg in the management of moderate-to-severe acute pain in patients in an emergency room (ER) setting.","primaryOutcome":{"measure":"Time-weighted Summed Pain Intensity Difference (SPID) Over the 1-hour (SPID1).","timeFrame":"One hour","effectByArm":[{"arm":"Sufentanil Sublingual Tablet 30 mcg","deltaMin":2.11,"sd":0.24}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":76},"commonTop":["Nausea","Vomiting","Oxygen saturation decreased","Somnolence"]}}